ATPBONE

Fighting osteoporosis by blocking nucleotides: purinergic signalling in bone formation and homeostasis

Coordinatore	REGION HOVEDSTADEN    more  Organization address address: KONGENS VAENGE 2 city: HILLEROD postcode: 3400 contact info Titolo: Mr. Nome: Jesper Thyge Cognome: Johansen Email: send email Telefono: 4538632104 Fax: 4538633906
Nazionalità Coordinatore	Denmark [DK]
Sito del progetto	http://www.atpbone.org/
Totale costo	4˙223˙079 €
EC contributo	2˙998˙682 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-01-01   -   2010-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	REGION HOVEDSTADEN  Organization address address: KONGENS VAENGE 2 city: HILLEROD postcode: 3400 contact info Titolo: Mr. Nome: Jesper Thyge Cognome: Johansen Email: send email Telefono: 4538632104 Fax: 4538633906	DK (HILLEROD)	coordinator	0.00
2	THE UNIVERSITY OF LIVERPOOL  Organization address address: Brownlow Hill, Foundation Building 765 city: LIVERPOOL postcode: L69 7ZX contact info Titolo: Mr. Nome: Colin Cognome: Cooper Email: send email Telefono: -9623 Fax: -9629	UK (LIVERPOOL)	participant	0.00
3	THE UNIVERSITY OF SHEFFIELD  Organization address address: FIRTH COURT WESTERN BANK city: SHEFFIELD postcode: S10 2TN contact info Titolo: Mr. Nome: Gill Cognome: Wells Email: send email Telefono: -2221504 Fax: -2221525	UK (SHEFFIELD)	participant	0.00
4	UNIVERSITA DEGLI STUDI DI FERRARA  Organization address address: SAVONAROLA 9 city: FERRARA postcode: 44100 contact info Titolo: Prof. Nome: Francesco Cognome: Di Virgilio Email: send email Telefono: 390532000000 Fax: 390532000000	IT (FERRARA)	participant	0.00
5	UNIVERSITE LIBRE DE BRUXELLES  Organization address address: Avenue Franklin Roosevelt 50 city: BRUXELLES postcode: 1050 contact info Titolo: Prof. Nome: Jean-Marie Cognome: Boeynaems Email: send email Telefono: 32-2-555.39.22 Fax: -646	BE (BRUXELLES)	participant	0.00
6	UNIVERSITEIT MAASTRICHT  Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD contact info Titolo: Dr. Nome: Joseph I H Cognome: Janssen Email: send email Telefono: -3881973 Fax: -3670298	NL (MAASTRICHT)	participant	0.00
7	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Dr. Nome: Michael Cognome: Browne Email: send email Telefono: +44(0)2076796135 Fax: +44(0)2076796502	UK (LONDON)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Osteoporosis is a disabling disease and the incidence is expected to increase significantly over the next decades due to an increase in the elderly population. This will lead to an enormous economical burden both in the European Union and in the rest of the world. Osteoporosis should be treated early in order to prevent the bone fractures related to the disease, and a number of anti-resorptive treatments exist that can reduce the loss of bone. However, the possibilities of regaining already lost bone are limited, as only one anabolic treatment option (parathyroid hormone (PTH) )is available on the market. In most countries PTH is restricted to the most severe cases of osteoporosis with multiple fractures. Thus new anabolic treatment options for osteoporosis are highly warranted. Purinergic signalling, where nucleotides such as ATP act as extracellular signalling molecules, is a rapidly expanding field. The purinergic system has plays a central role in bone physiology, and bone deposition and resorption are finely tuned by extracellular nucleotides. Furthermore, the 'purinergic system' is now believed to be one of the main transducing pathways of mechanical stimulation, a stimulus that is highly anabolic to bone. The overall aim of the proposal is to definitively prove the role of ATP and purinergic receptor signalling in the control of bone formation and homeostasis, thereby proving the potential of the system as a target for the development of new anabolic treatment regimens for osteoporosis. The aim will be addressed by examining the role of ATP as a signalling molecule in bone, the pathways and purinergic receptors involved in the signalling and their role in bone formation and homeostasis in vitro. Furthermore, translational studies in in vivo P2 receptor knock out mice will be used to show the role of the signalling pathways on bone, as well as small-scale clinical proof-of-concept studies to prove the potential of the system in targeting osteoporosis.'